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Abstract
Introduction Cancer is rare in adolescents and young adults
(AYA), but these patients have seen little improvement in
survival in contrast to most other age groups. Furthermore,
participation in research by AYAs is typically low. We
conducted a study to examine the feasibility of recruiting a
population-based sample of AYA survivors to examine
issues of treatment and health outcomes.
Methods Individuals diagnosed in 2007–08 and age 15–39
at the time of diagnosis with acute lymphocytic leukemia,
Hodgkin lymphoma, non-Hodgkin lymphoma, germ cell
cancer or sarcoma were identified by 7 Surveillance,
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mailed surveys within 14 months after diagnosis and again
a year later, and had medical records reviewed.
Results 525 (43%) of the eligible patients responded, 39%
refused and 17% were lost to follow-up. Extensive efforts
were required for most potential respondents (87%). 76%
of respondents completed the paper rather than online
survey version. In a multivariate model, age, cancer site,
education and months from diagnosis to the first mailing
of the survey were not associated with participation,
although males (p<0.01), Hispanics and non-Hispanic
blacks (p<0.001) were less likely to participate. 91% of
survivors completing the initial survey completed the
subsequent survey.
Discussion Despite the response rate, those who participated
adequately reflected the population of AYA cancer survivors.
The study demonstrates that cancer registries are valuable
foundations for conducting observational, longitudinal
population-based research on AYA cancer survivors.
Implications for Cancer Survivors Achieving a reasonable
response rate in this population is possible, but requires
extensive resources.
Keywords Adolescent cancer.Young adult cancer.
Survey.Response rates.Medical records.Consent forms
Introduction
Although cancer is rare in adolescents and young adults
(AYA), it is the leading cause of death in this age group
after unintentional injury, homicide and suicide [1].
Survival following a cancer diagnosis in AYAs (defined as
ages 15–39) has shown little improvement relative to other
age groups [2]. In particular, cancer patients diagnosed
between the ages of 25 and 35 have had no survival
improvement in more than 20 years [2]. Although scientific
evidence to understand reasons for this phenomenon is
limited, experts have speculated that the lack of improve-
ment in survival may be due to a combination of factors,
such as the lack of available clinical trials hampering efforts
to develop novel therapies,[3] lack of medical insurance,
poor access to medical care for the initial diagnosis and for
follow-up care, attitudes of invincibility, physicians’ low
suspicion of cancer resulting in delayed diagnosis, and
location and specialty of treating physicians [4].
To address several of these issues in AYA cancer patients,
the National Cancer Institute (NCI) in 2007, in partnership
with the Lance Armstrong Foundation (LAF), initiated an
observational cohort study to: 1) examine factors associated
with high quality cancer treatment in general community
practice, including the use of clinical trials and treatment
protocols, and 2) assess patient-reported outcomes, such as
health-related quality of life, unmet needs, and the impact of
cancer on psychosocial domains. The design and implemen-
tation of the Adolescent and Young Adult Health Outcomes
and Patient Experience (AYA HOPE) Study was motivated
and guided by the findings of a systematic review of the
science on AYA cancer patients [5].
Here we report on the feasibility of 1) recruiting AYA
cancer survivors, 2) developing and fielding a patient
survey with a subsequent survey to examine changes over
time and 3) obtaining patient (or guardian) consent to
review medical records. We focus on the practical chal-
lenges in recruiting and conducting research in AYA cancer
survivors identified through population-based registries
across the United States, and discuss potential strategies
to increase recruitment of these survivors.
Methods
Study setting and eligibility criteria
Patients were identified through seven population-based
Surveillance, Epidemiology and End-Results (SEER) pro-
gram cancer registries: Detroit; Seattle/Puget Sound; Los
Angeles County, San Francisco/Oakland, Greater California
(13 counties around Sacramento plus Orange County), and
the states of Iowa and Louisiana.
Conduct of this study required approval from 9 Institu-
tional Review Boards (IRBs) (7 registries, 1 state (California)
and the NCI IRB), which took 7 months. Several registries
experienced particularly long approval processes because the
inclusion of minors required changes to consent forms. No
concerns were raised by the IRB about survey content,
although there was concern about security of the online
survey that was resolved with a more complete explanation of
the security protocols. The online survey website included a
firewall, Virtual Private Network (VPN), an intrusion
detection system, and routine security checks of the computer
resources. Patients were given a website address, user name
and password in the initial mailing. Patients accessing the
online survey were required to create a new password upon
entering the system. This process made the survey accessible
only to the person with the new password. Once the survey
was submitted no further access was allowed.
Eligible patients were diagnosed between July 1, 2007
and October 31, 2008 with a first invasive, histologically
confirmed germ cell cancer, non-Hodgkin lymphoma
(NHL), Hodgkin lymphoma (HL), acute lymphocytic
leukemia, Ewing’s sarcoma, osteosarcoma, or rhabdomyo-
sarcoma (Appendix I), ages 15 through 39 years at
diagnosis, residents of the study area and able to read
English. The goal was to obtain 530 surveys completed 6–
14 months from the date of diagnosis. A small sample of
306 J Cancer Surviv (2011) 5:305–314deceased patients who were otherwise eligible was included
in the medical record review.
Data collection instruments
The survey (http://outcomes.cancer.gov/surveys/aya/),
which took approximately 20 min to complete, was
designed to be self-administered and address a number
of issues including the impact of cancer, health-related
quality of life, healthcare delivery, and reasons for not
participating in clinical trials. Survey development included
cognitive and usability testing with 24 AYA cancer survivor
volunteers.
Patients were asked to complete a healthcare provider
form by listing the names and addresses of all healthcare
providers and facilities providing care. The information was
used to supplement registry information and to request
medical records for data abstraction.
Patient recruitment
Before patients were contacted, the patient’s physician was
notified that his/her patient would be approached to
participate in the study. Physicians were asked to advise
study staff if there were reasons the patient should not be
contacted. If the staff had not heard from the physician in
3 weeks, they contacted the patient. Some physicians and
one state registry required active physician consent.
Eligible patients were mailed a cover letter, a brochure
introducing the study, an overall study consent document
(where required by the registry’s IRB), healthcare provider
form, a Health Insurance Portability and Accountability Act
(HIPAA) compliant consent for the release of medical
information, a paper survey, a web address for the online
survey, a pre-addressed stamped return envelope for study
materials, and a LIVESTRONG bracelet. If the patient was
a minor at the time of contact, study materials were mailed
to the parent/guardian and included a consent document
requiring signatures from the parent/guardian and a signa-
ture of assent from the minor.
Follow-up procedures for non-respondents included a
second mailing 3 weeks after the initial mailing, followed
by telephone calls from trained interviewers beginning
2 weeks after the second mailing. If needed, multiple
follow-up calls were made to ask the patient to complete
the survey over the telephone and mail the medical record
release and the healthcare provider form.
If study materials were returned marked undeliverable,
the staff employed a variety of tracing procedures to obtain
the correct address, including reviewing the cancer registry
database for updated information, contacting directory
assistance, obtaining information from healthcare providers,
hospital(s) and family members. Study sites also used
website directories (e.g., Google, Zabasearch), paid direc-
tory services (e.g., Accurint, Coles) and/or public records
(e.g., Department of Motor Vehicles, Voter Registration).
A few study sites sought new addresses by exploring
social networking websites. If a new address was not
found, the staff attempted to contact the individuals by
telephone. If the interviewer received an answering
machine a message was left; after leaving 2 messages no
additional messages were left. Phone calls were made at
different times during the day, evening and weekends. If
none of these efforts was successful, the patient was
classified as lost to follow-up.
Patients who completed the survey were sent a thank
you letter and $25.00 for the time spent completing it.
An additional $25.00 was provided for time spent
completing the healthcare provider and medical record
release forms.
Medical record retrieval
Medical records were collected from facilities listed on the
healthcare provider form. Information obtained included
type of healthcare facilities, physician subspecialties, tumor
characteristics and staging, diagnostic procedures, partici-
pation in active clinical trials, therapy provided, and
comorbid conditions.
Follow-up survey
We also conducted a follow-up survey, designed to be self-
administered by paper or online, to examine changes in
psychosocial outcomes and health-related quality of life
15–35 months following the initial diagnosis. Survey
development (http://outcomes.cancer.gov/surveys/aya/),
tracing and follow-up was similar to the methods used for
the initial survey. Participants were provided with $50 for
time spent completing the survey. No additional medical
record review was performed.
Analyses
Descriptive univariate analyses were conducted to com-
pare demographic and tumor characteristics of baseline
survey respondents and non-respondents based on data
collected by each SEER registry. We used the patient’s
address at the time of cancer diagnosis to determine area
level educational attainment and median family income at
the census tract level [6]. A multiple logistic regression
model was used to assess the association between clinical and
non-clinical factors and participation. Survey participants
were compared by survey mode, and follow-up survey
completion. A significance level of 0.05 (two tailed) was
used for all analyses.
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A total of 1,405 patients were identified as potentially
eligible (Fig. 1). Among registries that required physician
consent, only 6 physicians refused to allow their patient
to be contacted. Physicians identified 11 patients as
deceased and 9 as ineligible. Another 70 patients became
ineligible because they exceeded their 14-month eligibil-
ity date prior to contact. After mailing the survey (n=
1,309), we identified 16 deceased patients and 85 patients
ineligible because they did not speak English (56%),
they denied having cancer (9%), or due to other reasons
(34%).
Response rates
A total of 524 eligible patients completed the initial survey
and 1 patient completed only the medical record release
(Fig. 1), yielding a response rate of 43%. Of patients sent
the initial mailing, 87% required additional contact.
Of the refusals, 133 directly declined participation when
contacted and 341 patients never completed the surveys
despite repeated contacts (Fig. 1). Of patients lost to follow-
up, telephone numbers were found for 126, but several calls
to these numbers did not produce a mailing address. For the
remaining 83 patients, neither a valid telephone number nor
an address could be found.
Generalizability of the enrolled sample
We compared the characteristics of patients who participated
in the survey to non-responders (Table 1). In univariates
analyses, non-respondents were not significantly different
from responders by age, census tract education, or census
tract median family income. Response did vary by cancer
site (p<0.04) from 38% for acute lymphocytic leukemia and
sarcoma to 51% for HL. Females were more likely to
participate (p<0.0001). Non-Hispanic black (p<0.05) and
Hispanic (p<0.001) patients were less likely to respond than
non-Hispanic whites. Among non-respondents, non-
Hispanics whites and non-Hispanic Blacks were more likely
to refuse (p<0.001) while Hispanics (32%) were more than
twice as likely to be lost to follow-up as non-Hispanic white
(12%) or non-Hispanic black (14%) patients (data not
shown).
In a multivariate logistic regression model, we investi-
gated factors thought to be associated with response rate
(Table 2). Females were more likely to answer the survey
than were males (p <0.001). Compared to non-Hispanic
whites, Hispanics and non-Hispanic blacks were less likely
Physician Consent
Refused
N=6 
Potential Participants Mailed
Survey
N=1309 
Total Eligible Surveys Completed
N=524
Paper       Web     Telephone
N=397     N=115       N=12
Medical Record
Consents
N=499 
Medical Records
Obtained
N=490 
Refusals
N=474
Medical Record
Consent Refusals
N=26 
Lost to Follow-up
N=209
AYA HOPE PATIENT RECRUITMENT FLOWCHART
Potential Eligible Patients
N=1405
Ineligible
N=85
Deceased
N=16
Medical Record Consent only
N=1
Lost Survey
N=1
Deceased
N=11
Ineligible
N=79
Fig. 1 Patient number
flowsheet for the study
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associated with participation.
Response by survey mode
Some patients chose to complete the survey online (22%)
or over the telephone (2%) (Fig. 1 and Table 3). Compared
to patients in other age or racial/ethnic groups, fewer 20–
24 year-olds or non-Hispanic black patients and less than 10%
of sarcoma patients completed the survey online. Patients with
an Associate Degree or higher or who lived in higher
socioeconomic status census tracts, defined by education and
income, were more likely to complete the survey online.
Medical records
Among participants completing the survey, 5% refused to
sign a medical records release consent form (Fig. 1).
Medical records were obtained for 93% of all respondents.
However, we were unable to obtain medical records for
2% of consenting participants because the records were
lost within the healthcare facility or the facility failed to
provide them after multiple requests. Medical records
were obtained for a small sample (n=27) of deceased
patients primarily to assess any differences in the diagnosis
and treatment that might arise from excluding patients who
had died.
Follow-up survey
Of the 524 eligible participants who completed the initial
survey, 465 completed the follow-up survey, 34 were non-
responders, and 10 were lost to follow-up (Table 4). The
participation rate in the follow-up survey was over 91%
among survivors. Between the initial and subsequent
survey (8–17 months), 3% (n=15) of the patients died.
Table 1 Percent distribution of demographic characteristics for respondents and non-respondents
ALL Germ cell HL NHL Sarcoma All cancer sites
p-value
R NR R NR R NR R NR R NR R NR
(n=21) (n=35) (n=206) (n=304) (n=142) (n=136) (n=131) (n=167) (n=25) (n=41) (n=525) (n=683)
Age (years) p=0.0788
15–19 57.1 42.9 7.8 12.5 12.7 20.6 9.9 9.6 32.0 56.1 12.8 17.6
20–24 14.3 28.6 21.4 18.4 16.9 22.1 12.2 14.4 24.0 17.1 17.7 18.6
25–29 14.3 11.4 27.2 24.0 31.7 19.1 19.1 18.6 20.0 9.8 25.5 20.2
30–34 0 8.6 24.3 24.0 21.1 18.4 25.2 24.0 12.0 12.2 22.1 21.4
35–39 14.3 8.6 19.4 21.1 17.6 19.9 33.6 33.5 12.0 4.9 21.9 22.3
SEER Race/ethnicity p=0.0026
Hispanic 33.3 31.4 22.3 33.2 12.0 11.8 17.6 21.6 16.0 29.3 18.5 25.8
Non-Hispanic White 47.6 51.4 70.4 53.6 62.7 65.4 59.5 44.3 40.0 41.5 63.2 52.9
Non-Hispanic Black 9.5 2.9 2.4 4.6 12.0 15.4 10.7 16.8 16.0 12.2 8.0 10.1
Other/Unknown 9.5 14.3 4.9 8.6 13.4 7.4 12.2 17.4 28.0 17.1 10.3 11.3
Sex p<0.0001
Male 47.6 65.7 90.3 90.8 39.4 56.6 49.6 60.5 64.0 68.3 63.4 73.9
Female 52.4 34.3 9.7 9.2 60.6 43.4 50.4 39.5 36.0 31.7 36.6 26.1
Census: Median% HS Education (age 25 or older) p=0.0945
Not Available 0 0 0.5 0 0 1.5 0 0 0 0 0.2 0.3
<75% 23.8 25.7 28.2 33.2 26.1 24.3 26.0 28.1 24.0 41.5 26.7 30.3
75–90% 52.4 45.7 37.4 43.4 41.5 41.9 35.1 38.3 52.0 29.3 39.2 41.1
90+% 23.8 28.6 34.0 23.4 32.4 32.4 38.9 33.5 24.0 29.3 33.9 28.3
Census: median family income p=0.1102
Not available 0 0 0.5 0 0 1.5 0 0 0 0 0.2 0.3
<$45,000 19.0 34.3 31.1 38.5 28.9 28.7 29.0 33.5 40.0 39.0 29.9 35.1
$45–$65,000 47.6 34.3 36.9 34.2 36.6 30.9 38.9 32.9 32.0 26.8 37.5 32.8
$65,000+ 33.3 31.4 31.6 27.3 34.5 39.0 32.1 33.5 28.0 34.1 32.4 31.8
R respondent; NR non-respondent; ALL acute lymphocytic leukemia; HL Hodgkin lymphoma; NHL non-Hodgkin lymphoma
p-value=0.0372
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The goal of the AYA HOPE Study was to learn about
recruitment of AYAs, their cancer care and outcomes and to
determine the feasibility of collecting survey and detailed
medical record information on a representative population-
based sample of AYA cancer survivors. Our response rate
among eligible patients was 43%. This age group, partic-
ularly those ages 15–25 years, is mobile and difficult to
follow due to educational and employment opportunities,
marriage and other personal life changes.
Previous studies have shown that response rates of
young adults are lower than for older adults [7–9]. A survey
of adult NHL survivors identified from a cancer registry
had a 55% response rate, but patients were older and 2–
5 years post diagnosis [7]. Despite aggressive follow-up,
one recent health survey in adolescents ages 13–17 years
yielded a 40% response rate [8]. These adolescents had
been seen within the healthcare system in the previous year
and were recruited by that system. A national study of
childhood cancer survivors between 1994 and 2000
achieved a 62% completion rate with extensive resources
[9]. However, the denominator for the completion rate
included only those subjects who expressed an interest in
the study after being contacted by their treating institution.
As indicated by our follow-up survey, once individuals
agree to participate in a study, they are more likely to
complete subsequent surveys. The response rate in our
study might have been higher if, as in the NHL [7] study,
more time had elapsed since diagnosis. Some of the patients
eligible for our study who refused may still have been
under active treatment and may have agreed to participate
once therapy was completed.
Males and non-Hispanic black and Hispanic patients
were significantly less likely to participate, similar to
differences reported for cancer clinical trials [10, 11].
Significantly lower enrollment for minority compared to
white patients and for men compared to women was
reported for surgical trials [11]. This finding has been
shown not only in cancer, but in other diseases as well [12].
Although 37% of our respondents were racial/ethnic
minorities, it is likely to have been higher if translated
versions of the survey were available, as not speaking
English was the primary reason for ineligibility among our
population.
A variety of methods were used to maximize responses
to the mailing. We enclosed a LIVESTRONG bracelet that
added interest and bulk to the packet. One registry initially
used an overnight delivery service, but abandoned this
within a month. Response rates were lower than with
USPS. The overnight service did not leave packages if no
one was home, had limited re-delivery, no forwarding
addresses, and deliveries were limited to weekdays. While
we used a variety of approaches to enhance our response
rates, we did not send pre-notification letters or postcards.
Research has suggested this may not increase the response
rate [12], but it would have identified incorrect addresses at
a lower cost than mailing the complete packet.
Overall, 87% of the identified sample required at least
one additional mailing or telephone contact. An address or
telephone number could not be found for 16% of patients
identified as eligible, similar to the 15% reported by the
childhood cancer survivors study [9]. Although we likely
had the correct phone number for some patients, no one
answered our calls. With the increased use of caller
identification, patients may have been screening calls from
unrecognized phone numbers. It is possible that calls
originating from patients’ own medical institutions may
have yielded better responses, although a response rate of
Table 2 Multivariable analysis examining characteristics associated
withresponsevs.non-responsetotheAYAHOPEStudyBaselineSurvey
95% Confidence
Interval
Variable OR Lower Upper p-value
Age at diagnosis (years) 0.06
15–19 1.0
20–24 1.3 0.9 2.0
25–29 1.8 1.2 2.7
30–34 1.5 0.97 2.2
35–39 1.4 0.9 2.0
SEER Racial/ethnicity 0.01
Non-Hispanic White 1.0
Hispanic 0.6 0.5 0.9
Non-Hispanic Black 0.6 0.4 0.9
Other/Unknown 0.7 0.5 1.0
SEER Sex <0.001
Male 1.0
Female 1.7 1.3 2.2
Cancer site 0.60
Acute lymphocytic leukemia 1.0
Germ cell cancer 1.1 0.6 2.0
Hodgkin lymphoma 1.4 0.7 2.5
Non-Hodgkin lymphoma 1.1 0.6 2.0
Sarcoma 1.1 0.5 2.3
Census:% HS education
(age 25 or older)
0.31
<75% 1.0
75–90% 0.9 0.7 1.2
90%+ 1.1 0.8 1.6
Months from diagnosis to
initial mailing of survey
1.0 0.9 1.01 0.14
OR>1.0 indicates more likely to respond; OR<1.0 indicates less
likely to respond.
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N % N% N%
Age at diagnosis (years)
15–19 51 76.1% 14 20.9% 2 3.0%
20–24 75 80.6% 14 15.1% 4 4.3%
25–29 99 73.9% 31 23.1% 4 3.0%
30–34 84 73.0% 29 25.2% 2 1.7%
35–39 88 76.5% 27 23.5% 0
SEER Race/ethnicity
Hispanic 75 78.1% 19 19.8% 2 2.1%
Non-Hispanic White 252 75.9% 72 21.7% 8 2.4%
Non-Hispanic Black 34 81.0% 6 14.3% 2 4.8%
Other/Unknown 36 66.7% 18 33.3% 0
SEER Sex
Male 240 72.3% 82 24.7% 10 3.0%
Female 157 81.8% 33 17.2% 2 1.0%
Cancer site
a
ALL 18 85.7% 3 14.3% 0
NHL 95 72.5% 32 24.4% 4 3.1%
HL 108 76.1% 32 22.5% 2 1.4%
Germ cell 153 74.6% 46 22.4% 6 2.9%
Sarcoma 23 92.0% 2 8.0% 0
Education
Less than high school diploma 53 91.3% 4 6.9% 1 1.7%
Completed high school 69 75.8% 16 17.6% 6 6.6%
Some college/vocational/training 106 76.8% 30 21.7% 2 1.4%
Associate Degree 38 71.7% 15 28.3% 0
College graduate 94 71.8% 34 26.0% 3 2.3%
Post-graduate education 35 68.6% 16 31.4% 0
Missing 2 100.0% 0 0
Census:% HS Education (age 25 or older)
Not Available 1 100.0% 0 0
<75% 109 78.4% 24 17.3% 6 4.3%
75–90% 166 80.6% 35 17.0% 5 2.4%
90%+ 121 68.0% 56 31.5% 1 0.6%
Census: median family income
Not Available 1 100.0% 0 0
<$45,000 127 81.4% 22 14.1% 7 4.5%
$45,000–$65,000 149 75.6% 45 22.8% 3 1.5%
$65,000+ 120 70.6% 48 28.2% 2 1.2%
SEER Registry
Northern California 81 65.9% 38 30.9% 4 3.3%
Los Angeles 77 81.1% 17 17.9% 1 1.1%
Seattle-Puget Sound 63 74.1% 22 25.9% 0
Louisiana 52 74.3% 12 17.1% 6 8.6%
Greater California 43 72.9% 16 27.1% 0
Metropolitan Detroit 44 84.6% 7 13.5% 1 1.9%
Iowa 37 92.5% 3 7.5% 0
Table 3 Mode of survey
completion by patient
characteristics, AYA HOPE
study
aALL acute lymphocytic
leukemia; HL Hodgkin
lymphoma; NHL non-Hodgkin
lymphoma
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N% N% N % N %
Age at diagnosis (years)
15–19 63 94.0% 1 1.5% 0 3 4.5%
20–24 81 87.1% 8 8.6% 2 2.2% 2 2.2%
25–29 114 85.1% 13 9.7% 5 3.7% 2 1.5%
30–34 103 89.6% 6 5.2% 5 4.3% 2 1.7%
35–39 104 90.4% 7 6.1% 3 2.6% 1 0.9%
SEER Race/ethnicity
Hispanic 83 86.5% 6 6.2% 3 3.1% 5 5.2%
Non-Hispanic White 298 89.8% 22 6.6% 8 2.4% 4 1.2%
Non-Hispanic Black 35 83.3% 4 9.5% 2 4.8% 1 2.4%
Other/Unknown 49 90.7% 3 5.6% 2 3.7% 0
SEER Sex
Male 287 86.4% 26 7.8% 11 3.3% 9 2.7%
Female 178 92.7% 9 4.7% 4 2.1% 1 0.5%
Cancer site
a
ALL 18 85.7% 1 4.8% 1 4.8% 1 4.8%
NHL 113 86.3% 9 6.9% 7 5.3% 2 1.5%
HL 130 91.5% 10 7.0% 1 0.7% 1 0.7%
Germ cell 181 88.3% 15 7.3% 4 2.0% 6 2.9%
Sarcoma 23 92.0% 0 2 8.0% 0
Education
Less than high school diploma 51 87.9% 3 5.2% 3 5.2% 1 1.7%
Completed high school 79 86.8% 8 8.8% 1 1.1% 3 3.3%
Some college/vocational training 123 89.1% 8 5.8% 4 2.9% 3 2.2%
Associate degree 47 88.7% 5 9.4% 1 1.9% 0
College graduate 119 90.8% 7 5.3% 4 3.1% 1 0.8%
Post-graduate education 45 88.2% 3 5.9% 2 3.9% 1 2.0%
Missing 1 50.0% 0 0 1 50.0%
Census:% HS education (age 25 or older)
Not Available 1 100.0% 0 0 0
<75% 121 87.1% 9 6.4% 5 3.6% 5 3.6%
75–90% 182 88.3% 14 6.8% 7 3.4% 3 1.5%
90%+ 161 90.4% 12 6.7% 3 1.7% 2 1.1%
Census: median family income
Not Available 1 100.0% 0 0 0
<$45,000 131 84.0% 13 8.3% 6 3.8% 7 4.5%
$45,000–$65,000 177 89.8% 14 7.1% 5 2.5% 1 0.5%
$65,000+ 156 91.8% 8 4.7% 4 2.4% 2 1.2%
SEER Registry
Northern California 108 87.8% 9 7.3% 2 1.6% 4 3.3%
Los Angeles 81 85.3% 7 7.3% 4 4.2% 4 4.2%
Seattle-Puget Sound 76 89.4% 6 7.1% 3 3.5% 0
Louisiana 60 85.7% 6 8.6% 4 5.7% 0
Greater California 57 96.6% 0 1 1.7% 1 1.7%
Metropolitan Detroit 49 94.2% 1 1.9% 1 1.9% 1 1.9%
Iowa 34 85.0% 6 15.0% 0 0
Table 4 Follow-up survey
completion by patient
characteristics, AYA HOPE
Study
aALL acute lymphocytic
leukemia; HL Hodgkin
lymphoma; NHL non-Hodgkin
lymphoma
312 J Cancer Surviv (2011) 5:305–314only 40% was reported by a study conducted within
patients in a healthcare organization [8].
Some survivors refused to participate in any part of our
study because of the HIPAA medical release form.
Evidence from a community-based, randomized, mixed-
mode survey (n=6,939) reported the inclusion of a
minimally burdensome version of HIPAA authorization
form reduced survey response rates by up to 15% [13].
Simply requiring a signature reduces the response rate.
Nelson reported that response rates were 58% at locations
requiring no advanced permission to contact the individual
compared to 27% for those requiring written permission
from the individual [14].
Although some staff used social networking websites to
find addresses, we did not use this approach to communicate
with patients because registries did not request IRB approval
for this type of contact. We were concerned about the
confidentiality of a social network contact and identification
of the correct person. However, in future studies, social
networking websites may be a useful method of contact [15].
This may increase participation as email/web communication
is used extensively among young people. However, methods
to ensure patient confidentiality are required.
The majority of patients in our study completed the
paper rather than the online version. Future studies might
evaluate different approaches to increase participation and
the use of online surveys. A web address included in the
initial mailing that links to a well-designed website
describing the study and reasons to participate, and includes
the survey as well as other survivorship information might
entice AYAs to participate. However, it is possible that
AYAs simply prefer to complete the paper version of the
survey. A study in Olmstead County found the inclusion of
an internet option decreased the response rate [16] while a
study in Norway found no increase with the online option
[17]. One possibility is that unless thrown away, a paper
survey is a constant reminder, whereas a computer can be
turned off.
Conclusion
The AYA HOPE Study demonstrates that recruiting and
following a diverse population of AYA survivors diagnosed
with different cancers and living throughout the US can be
accomplished using population-based registries. However,
it is important for researchers to be realistic in their
expectations, recognizing that this population is mobile
and difficult to contact. Achieving a high response rate is
challenging, requiring more extensive resources for follow-
up. Despite these limitations and challenges, the AYA
HOPE Study confirms that the use of cancer registries is a
valuable foundation for conducting observational, longitu-
dinal population-based research on younger, non-pediatric
cancer survivors.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Appendix I
Sites and tumor morphologies (ICD-O-3 codes) included:
non-Hodgkin lymphoma (9590–9596, 9670, 9671,
9673, 9675, 9678–9680, 9684, 9687, 9689–9691,
9695, 9698–9702, 9705, 9708, 9709, 9714–9719,
9727–9729);
Hodgkin lymphoma (9650–9655, 9659, 9663–9665,
9667);
germ cell cancer (9060–9091, 9100–9102) excluding
patients with intracranial and intraspinal tumors (C700-
C729, C751-C753);
acute lymphocytic leukemia (9820, 9832–9837);
Ewing’s sarcoma (9260, 9365), osteosarcoma (9180–
9187, 9192–9195) and rhabdomyosarcoma (8900–8921):
Sarcomas arising in the central nervous system (C700-
C729) were excluded.
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